Multiple Sclerosis Therapeutics, Second Edition

✍ Scribed by Richard A. Rudick, Jeffrey A. Cohen

• Year: 2002
• Tongue: English
• Leaves: 867
• Edition: 2
• Category: Library

✦ Synopsis

This revised text examines the most salient aspects of multiple sclerosis that impact clinical trial design, the development of new disease therapies, and, most importantly, patient care. An international team of contributors discusses the clinical course of multiple sclerosis, its clinical heterogeneity, and the presence of subclinical disease activity in the early stages of the disease. The text includes several new chapters, such as those on functional imaging, sex hormones and pregnancy-related factors, complementary and alternative treatments, management of cognitive impairment and rehabilitative approaches. This book is essential for any clinician who works with MS patients.

✦ Table of Contents

Book Cover......Page 1
Half-Title......Page 3
Title......Page 5
Copyright......Page 6
Contents......Page 7
Contributors......Page 11
Preface to First Edition......Page 23
Preface to Second Edition......Page 26
Acknowledgements......Page 28
I Introduction......Page 30
1 Aspects of multiple sclerosis that relate to clinical trial design and treatment......Page 32
II Clinical trial methodology......Page 51
2 Measures of neurologic impairment and disability in multiple sclerosis......Page 52
3 Assessment of neuropsychological function in multiple sclerosis......Page 67
4 Health-related quality of life assessment in multiple sclerosis......Page 95
5 Magnetic resonance imaging in multiple sclerosis: an overview......Page 115
6 Measures of gadolinium enhancement in multiple sclerosis......Page 132
7 Measures of magnetization transfer in multiple sclerosis......Page 165
8 Measures of T1 and T2 relaxation in multiple sclerosis......Page 205
9 Measurement of central nervous system atrophy......Page 226
10 Measures to quantify axonal damage in vivo based on magnetic resonance spectroscopy in multiple sclerosis......Page 249
11 Functional imaging in multiple sclerosis......Page 264
12 Use of cost analyses to improve understanding of the therapeutic trade-offs for multiple sclerosis......Page 280
13 Ethical considerations in multiple sclerosis clinical trials......Page 290
14 The process of drug development and approval in the USA, the European Union, and Canada......Page 301
15 Sponsors, monitoring committees and investigators: the investigator’s perspective......Page 317
16 Guidelines for clinical trials of new therapeutic agents in multiple sclerosis: reporting extended results from phase III clinical trials......Page 321
17 The failed clinical trial in multiple sclerosis......Page 326
18 The challenge of long-term studies in multiple sclerosis: use of pooled data, historical controls, and observational studies to determine efficacy......Page 337
19 Emerging concepts of pathogenesis: relationship to therapies for multiple sclerosis......Page 350
III Clinical trials of disease-modifying therapy......Page 388
33 Complementary and alternative treatments in multiple sclerosis......Page 638
32 Sex hormones and other pregnancy-related factors with therapeutic potential in multiple sclerosis......Page 622
31 Combination therapies in multiple sclerosis......Page 610
30 Emerging disease-modifying therapies for multiple sclerosis......Page 601
29 Treatment of multiple sclerosis by hematopoietic stem cell transplantation......Page 587
28 Cyclophosphamide treatment of multiple sclerosis......Page 565
27 Treatment of multiple sclerosis with methylprednisolone......Page 541
26 Therapeutic plasma exchange for multiple sclerosis......Page 524
25 Intravenous immunoglobulin to treat multiple sclerosis......Page 507
24 Use of mitoxantrone to treat multiple sclerosis......Page 479
23 Glatiramer acetate as therapy for multiple sclerosis......Page 447
22 Biological responses to type I interferons: relationship to therapeutic effects in multiple sclerosis......Page 431
21 Interferons in secondary progressive multiple sclerosis......Page 415
20 Interferons in relapsing-remitting and secondary progressive multiple sclerosis......Page 389
IV Disease-modifying drug therapy in clinical practice......Page 652
43 Rehabilitation in multiple sclerosis patients......Page 831
42 Management of cognitive impairment in multiple sclerosis......Page 817
41 Treatment of tremor caused by multiple sclerosis......Page 804
40 Treatment of pain, paresthesias, and paroxysmal disorders in multiple sclerosis......Page 786
39 Treatment of disorders of mood and affect in multiple sclerosis......Page 746
38 Management of bladder and sexual dysfunction in multiple sclerosis......Page 711
37 Management of spasticity in multiple sclerosis......Page 698
36 Fatigue in multiple sclerosis......Page 686
35 Treatment for patients with primary progressive multiple sclerosis......Page 675
34 Disease-modifying drug therapy for multiple sclerosis in clinical practice......Page 653
Index......Page 840